

Biotin anti-mouse/human CD45R/B220 Antibody

Catalog# / Size	103203 / 50 µg 103204 / 500 µg
Clone	RA3-6B2
Regulatory Status	RUO
Other Names	B220
Isotype	Rat IgG2a, κ
Description	CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL- <i>Fas^{lpr}</i> and MRL- <i>Fas^{gld}</i> mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

Product Details

Verified Reactivity	Mouse, Human
Reported Reactivity	Cat
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Abelson murine leukemia virus-induced pre-B tumor cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application	FC - Quality tested IHC-F - Verified
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µl volume. For immunohistochemistry, a concentration range of 5.0 - 10 µg/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation ¹ , <i>in vitro</i> and <i>in vivo</i> modulation of B cell responses ²⁻⁴ , immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections ^{5,6} , and spatial biology (IBEX) ^{14,15} .
Application References	1. Coffman RL. 1982. <i>Immunol. Rev.</i> 69:5. (IP) 2. George A, <i>et al.</i> 1994. <i>J. Immunol.</i> 152:1014. (Activ) 3. Asensi V, <i>et al.</i> 1989. <i>Immunology</i> 68:204. (Activ) 4. Domiati-Saad R, <i>et al.</i> 1993. <i>J. Immunol.</i> 151:5936. (Activ) 5. Hata H, <i>et al.</i> 2004. <i>J. Clin. Invest.</i> 114:582. (IHC) 6. Monteith CE, <i>et al.</i> 1996. <i>Can. J. Vet. Res.</i> 60:193. (IHC) 7. Shih FF, <i>et al.</i> 2006. <i>J. Immunol.</i> 176:3438. (FC) 8. Chang C L-T, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:6984. 9. Fazilleau N, <i>et al.</i> 2007. <i>Nature Immunol.</i> 8:753.
(PubMed link indicates BioLegend citation)	

10. Lang GL, *et al.* 2008. *Blood* 111:2158. [PubMed](#)
11. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
12. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
13. Murakami R, *et al.* 2013. *PLoS One.* 8:73270. [PubMed](#)
14. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
15. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Grigsby SM, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
2. Hutter K, *et al.* 2022. *Front Immunol.* 13:967914. [PubMed](#)
3. Hu J, *et al.* 2019. *Am J Transl Res.* 3.043055556. [PubMed](#)
4. Drobek A, *et al.* 2015. *J Immunol.* 195: 3416 - 3426. [PubMed](#)
5. Florentin J, *et al.* 2022. *Front Immunol.* 13:882484. [PubMed](#)
6. Schloss MJ, *et al.* 2022. *Nat Immunol.* 23:605. [PubMed](#)
7. Guo F, *et al.* 2022. *Front Immunol.* 13:833100. [PubMed](#)
8. Zhou L, *et al.* 2021. *Cell Mol Immunol.* 18:698. [PubMed](#)
9. Lidak T, *et al.* 2021. *Int J Mol Sci.* 22: . [PubMed](#)
10. Domingues AF, *et al.* 2020. *Elife.* 9:e51754. [PubMed](#)
11. Wang L, *et al.* 2019. *Cell Rep.* 29:1848. [PubMed](#)
12. Thierry GR, *et al.* 2018. *J Exp Med.* 215:2972. [PubMed](#)
13. Zhu C, *et al.* 2018. *Sci Rep.* 5.113194444. [PubMed](#)
14. Tanimura N *et al.* 2018. *Developmental cell.* 46(5):581-594 . [PubMed](#)
15. Davis FM, *et al.* 2020. *J Immunol.* 2503:204. [PubMed](#)
16. Bouchareychas L, *et al.* 2021. *iScience.* 24(8):102847. [PubMed](#)
17. Chappaz S, *et al.* 2021. *Cell Reports.* 36(3):109430. [PubMed](#)
18. Geiger SS, *et al.* 2021. *Nature Communications.* 12(1):2745. [PubMed](#)
19. Boyd DF, *et al.* 2020. *Nature.* 587:466. [PubMed](#)
20. Han X, *et al.* 2017. *Int J Mol Sci.* 10.3390/ijms18050942. [PubMed](#)
21. Matsumoto R, *et al.* 2021. *Front Pharmacol.* 12:715752. [PubMed](#)
22. Yu VWC *et al.* 2016. *Cell.* 167(5):1310-1322 . [PubMed](#)
23. Matson CA, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:14342. [PubMed](#)
24. Yang X, *et al.* 2020. *Blood Sci.* 2:89. [PubMed](#)
25. Castellanos CA, *et al.* 2021. *Sci Immunol.* 6:eabh0707. [PubMed](#)
26. Álvaro de Mingo Pulido *et al.* 2018. *Cancer cell.* 33(1):60-74 . [PubMed](#)
27. de Mingo Pulido , *et al.* 2021. *Immunity.* 54(6):1154-1167.e7. [PubMed](#)
28. Browning LM, *et al.* 2020. *Cell Rep.* 33:108219. [PubMed](#)
29. Zong L, *et al.* 2021. *NPJ Aging Mech Dis.* 7:25. [PubMed](#)
30. Li Q *et al.* 2018. *Immunity.* 48(2):258-270 . [PubMed](#)
31. Mann M, *et al.* 2018. *Cell Rep.* 25:2992. [PubMed](#)
32. Bian Y, *et al.* 2017. *PLoS Pathog.* 13:e1006384. [PubMed](#)
33. Davis FM, *et al.* 2019. *Arterioscler Thromb Vasc Biol.* 39:2353. [PubMed](#)
34. Fukushima T, *et al.* 2019. *Cell Rep.* 29:4144. [PubMed](#)
35. Nagaoka M, *et al.* 2014. *J Immunol.* 193:2812. [PubMed](#)
36. Van de Velde L, *et al.* 2016. *Cell Rep.* 17:2247-2258. [PubMed](#)
37. Jing Zhou, Jun Jin, Toshihisa Kawai 2016. *Sci Rep.* 6:39105. [PubMed](#)
38. Xu X, *et al.* 2020. *J Cell Biol.* 219:00:00. [PubMed](#)
39. Liu X, *et al.* 2021. *eLife.* 0.4166666666666667. [PubMed](#)
40. Yamamoto K, *et al.* 2021. *Cell Reports.* 36(8):109576. [PubMed](#)
41. Dey A *et al.* 2019. *The EMBO journal.* 38(7) pii: e100293. [PubMed](#)
42. Liu YY, *et al.* 2020. *Chin Med J (Engl).* 133:1688. [PubMed](#)
43. Olsson A, *et al.* 2016. *Nature.* 10.1038/nature19348. [PubMed](#)
44. Kitano M, *et al.* 2016. *Proc Natl Acad Sci U S A.* 113: 1044 - 1049. [PubMed](#)
45. Wang L, *et al.* 2021. *Cancer Immunol Res.* 9:348. [PubMed](#)
46. Charmsaz S, *et al.* 2015. *PLoS One.* 10:130692. [PubMed](#)
47. Kurkewich J, *et al.* 2016. *PLoS One.* 11: 0161468. [PubMed](#)
48. Davidson S, *et al.* 2016. *EMBO Mol Med.* 8: 1099 - 1112. [PubMed](#)
49. Jassinskaja M, *et al.* 2021. *Cell Reports.* 34(12):108894. [PubMed](#)
50. Levine LS, *et al.* 2021. *Immunity.* 54(4):829-844.e5. [PubMed](#)
51. Zhang Y, *et al.* 2020. *J Immunol.* 204:3248. [PubMed](#)
52. Kotaki R, *et al.* 2020. *Sci Rep.* 10:13554. [PubMed](#)
53. Prados A, *et al.* 2021. *Nat Immunol.* 22:510. [PubMed](#)
54. Hurrell BP, *et al.* 2019. *Cell Rep.* 29:4509. [PubMed](#)
55. Yu VWC, *et al.* 2017. *Cell.* 168:944. [PubMed](#)
56. Onodera T, *et al.* 2019. *J Immunol.* 203:3282. [PubMed](#)
57. Xu L *et al.* 2017. *Immunity.* 47(3):538-551 . [PubMed](#)
58. Matsumura T *et al.* 2019. *Cell Rep.* 27(2):561-571 . [PubMed](#)
59. Chen X *et al.* 2017. *Cell stem cell.* 21(6):747-760 . [PubMed](#)
60. Ishisono K, Yabe T, and Kita K 2017. *J Nutr Biochem.* . 10.1016/j.jnutbio.2017.07.016. [PubMed](#)
61. Dong S, *et al.* 2021. *Nature.* 591:117. [PubMed](#)
62. Dietmar Herndler-Brandstetter *et al.* 2018. *Immunity.* 48(4):716-729 . [PubMed](#)
63. Vural A, *et al.* 2019. *J Immunol.* 202:1510. [PubMed](#)
64. Hulsmans M *et al.* 2017. *Cell.* 169(3):510-522 . [PubMed](#)
65. Nishime C, *et al.* 2015. *J Immunol.* 195: 1883-1890. [PubMed](#)
66. Derecka M, *et al.* 2020. *Nat Immunol.* 261:21. [PubMed](#)
67. D'Agostino MR, *et al.* 2022. *STAR Protoc.* 3:101652. [PubMed](#)
68. Chen M, *et al.* 2021. *Cancer Discov.* 11:194. [PubMed](#)
69. Perez E, *et al.* 2020. *J Immunol.* 205:2489. [PubMed](#)
70. Frodermann V, *et al.* 2019. *Nat Med.* 25:1761. [PubMed](#)
71. Chauveau A, *et al.* 2020. *Immunity.* 52:794. [PubMed](#)

72. Khanom US, *et al.* 2019. J Immunol. 203:881. [PubMed](#)
73. Milner JJ, *et al.* 2020. Immunity. 52(5):808-824.e7. [PubMed](#)
74. Zhou Z, *et al.* 2022. Infect Immun. 90:e0045321. [PubMed](#)
75. Wang F, *et al.* 2021. Cell. 184(2):422-440.e17. [PubMed](#)
76. Au-Yeung BB, *et al.* 2017. J Immunol. 198:2445. [PubMed](#)
77. Leyva-Castillo JM *et al.* 2019. Immunity. 50(5):1262-1275. [PubMed](#)
78. Sevin M, *et al.* 2018. Nat Commun. 9:1431. [PubMed](#)
79. Yi W, *et al.* 2021. Cell Reports. 34(13):108922. [PubMed](#)
80. Gally F, *et al.* 2013. Am J Physiol Lung Cell Mol Physiol. 305:64. [PubMed](#)
81. Aichinger M, *et al.* 2013. J Exp Med. 210:287. [PubMed](#)
82. Zhai X, *et al.* 2021. Sci Adv. 7:eabk0490. [PubMed](#)
83. Gamrekashvili J, *et al.* 2021. Bio Protoc. 11:e4007. [PubMed](#)
84. Galle-Treger L, *et al.* 2019. Nat Commun. 10:713. [PubMed](#)
85. Balzano M *et al.* 2019. Cell reports. 26(12):3257-3271. [PubMed](#)
86. Yang BH, *et al.* 2020. Cell Reports. 27(12):3629-3645.e6. [PubMed](#)
87. Akkaya B, *et al.* 2017. J Immunol Methods. 441:67. [PubMed](#)
88. Gao Y, *et al.* 2020. Immunity. 52(6):1007-1021.e8. [PubMed](#)
89. Tian Q, *et al.* 2021. Infect Immun. 89:e0020521. [PubMed](#)
90. Zeis P, *et al.* 2020. Immunity. 53:775. [PubMed](#)
91. Shih F, *et al.* 2006. J Immunol. 176:3438. [PubMed](#)
92. Frohner IE, *et al.* 2020. Cell Rep. 30:3171. [PubMed](#)
93. Kamata T, *et al.* 2020. Cell Reports. 31(12):107802. [PubMed](#)
94. Bagadia P, *et al.* 2019. Nat Immunol. 20:1174. [PubMed](#)
95. Duarte D, *et al.* 2018. Cell Stem Cell. 22:64. [PubMed](#)
96. Soukupova M, *et al.* 2021. Mol Ther Methods Clin Dev. 21:399. [PubMed](#)
97. Haase P, *et al.* 2020. Eur J Immunol. 50:558. [PubMed](#)
98. Scortegagna M, *et al.* 2020. Nat Commun. 11:99. [PubMed](#)
99. Schönberger K, *et al.* 2022. STAR Protoc. 3:101408. [PubMed](#)
100. Zhang MH, *et al.* 2020. Front Immunol. 11:560. [PubMed](#)
101. Oliveira AC *et al.* 2017. eLife. 6 pii: e30883. [PubMed](#)
102. Bajarña S, *et al.* 2022. iScience. 25:103732. [PubMed](#)
103. Iwata A, *et al.* 2017. Nat Immunol. 18:563. [PubMed](#)
104. Rohrbeck L, *et al.* 2020. Immunol Cell Biol. [PubMed](#)
105. Mohrin M, *et al.* 2021. Aging Cell. 20:e13313. [PubMed](#)
106. Rai S, *et al.* 2022. Nat Commun. 13:5346. [PubMed](#)
107. Zhang C, *et al.* 2018. Cell Res. 28:323. [PubMed](#)
108. Park DS, *et al.* 2019. PLoS Comput Biol. 15:e1006913. [PubMed](#)
109. Yoshida H, *et al.* 2019. Cell. 176:897. [PubMed](#)
110. Lefkopoulos S, *et al.* 2020. Immunity. 53(5):934-951.e9. [PubMed](#)
111. Wang J, *et al.* 2020. Cell Stem Cell. 27(1):81-97. [PubMed](#)
112. Han P, *et al.* 2020. Sci Adv. 6:eaaz1580. [PubMed](#)
113. Säwen P *et al.* 2018. eLife. 7 pii: e41258. [PubMed](#)
114. Hsia HC, *et al.* 2017. J Leukoc Biol. 101:1053. [PubMed](#)
115. Luo H, *et al.* 2019. Cell Rep. 26:945. [PubMed](#)
116. Riedel SS, *et al.* 2021. Molecular Cell. 81(11):2332-2348.e9. [PubMed](#)
117. Rossnagl S, *et al.* 2016. PLoS Biol. 14: 1002562. [PubMed](#)
118. Matsuzaki Y, *et al.* 2015. Biomed Rep. 1: 91 - 97. [PubMed](#)
119. Rappe JCF, *et al.* 2021. J Exp Med. 218:. [PubMed](#)
120. Waldman MM, *et al.* 2022. Front Immunol. 13:856977. [PubMed](#)
121. Qin J, *et al.* 2007. J Immunol. 179:6799. [PubMed](#)
122. Shen H, *et al.* 2020. Sci Rep. 10:19453. [PubMed](#)
123. Heyde A, *et al.* 2021. Cell. 184(5):1348-1361.e22. [PubMed](#)
124. Li ZG, *et al.* 2020. Chin Med J (Engl). 1943:133. [PubMed](#)
125. Cielias DP, *et al.* 2022. STAR Protoc. 3:101464. [PubMed](#)
126. Johnson JL *et al.* 2018. Immunity. 48(2):243-257. [PubMed](#)
127. Nabekura T, *et al.* 2020. Immunity. 96:52. [PubMed](#)
128. Bae S, *et al.* 2021. Cell Reports. 35(11):109264. [PubMed](#)
129. Young K, *et al.* 2021. Cell Stem Cell. [PubMed](#)
130. Becklund B, *et al.* 2016. Sci Rep. 6:30842. [PubMed](#)

RRID AB_312988 (BioLegend Cat. No. 103203)
 AB_312989 (BioLegend Cat. No. 103204)

Antigen Details

Structure	Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution	B cells, T cell subset, NK cell subset
Function	Phosphatase, T and B cell activation
Ligand/Receptor	Galectin-1, CD2, CD3, CD4
Cell Type	B cells, NK cells, T cells
Biology Area	Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers

Molecular Family CD Molecules

Antigen References

1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, *et al.* 1993. *Annu. Rev. Immunol.* 12:85.
3. Kishihara K, *et al.* 1993. *Cell* 74:143.
4. Pulido R, *et al.* 1988. *J. Immunol.* 140:3851.

Gene ID [19264](#)
[5788](#)

Related Protocols


[Immunohistochemistry Protocol for Frozen Sections](#)

[Cell Surface Flow Cytometry Staining Protocol](#)


Other Formats

Alexa Fluor® 594 anti-mouse/human CD45R/B220, APC anti-mouse/human CD45R/B220, Biotin anti-mouse/human CD45R/B220, FITC anti-mouse/human CD45R/B220, PE anti-mouse/human CD45R/B220, PE/Cyanine5 anti-mouse/human CD45R/B220, Purified anti-mouse/human CD45R/B220, PE/Cyanine7 anti-mouse/human CD45R/B220, APC/Cyanine7 anti-mouse/human CD45R/B220, Alexa Fluor® 488 anti-mouse/human CD45R/B220, Alexa Fluor® 647 anti-mouse/human CD45R/B220, Pacific Blue™ anti-mouse/human CD45R/B220, Alexa Fluor® 700 anti-mouse/human CD45R/B220, PerCP anti-mouse/human CD45R/B220, PerCP/Cyanine5.5 anti-mouse/human CD45R/B220, Brilliant Violet 421™ anti-mouse/human CD45R/B220, Brilliant Violet 570™ anti-mouse/human CD45R/B220, Brilliant Violet 650™ anti-mouse/human CD45R/B220, Brilliant Violet 605™ anti-mouse/human CD45R/B220, Brilliant Violet 785™ anti-mouse/human CD45R/B220, Brilliant Violet 510™ anti-mouse/human CD45R/B220, Purified anti-mouse/human CD45R/B220 (Maxpar® Ready), Brilliant Violet 711™ anti-mouse/human CD45R/B220, PE/Dazzle™ 594 anti-mouse/human CD45R/B220, APC/Fire™ 750 anti-mouse/human CD45R/B220, Brilliant Violet 750™ anti-mouse/human CD45R/B220, TotalSeq™-A0103 anti-mouse/human CD45R/B220, Spark Blue™ 550 anti-mouse/human CD45R/B220, Spark NIR™ 685 anti-mouse/human CD45R/B220, TotalSeq™-B0103 anti-mouse/human CD45R/B220, Ultra-LEAF™ Purified anti-mouse/human CD45R/B220, TotalSeq™-C0103 anti-mouse/human CD45R/B220, PE/Fire™ 640 anti-mouse/human CD45R/B220, APC/Fire™ 810 anti-mouse/human CD45R/B220, PE/Fire™ 700 anti-mouse/human CD45R/B220, Spark Violet™ 538 anti-mouse/human CD45R/B220, Spark YG™ 581 anti-mouse/human CD45R/B220, Spark YG™ 570 anti-mouse/human CD45R/B220, PE/Fire™ 810 anti-mouse/human CD45R/B220, Spark Blue™ 574 anti-mouse/human CD45R/B220 Antibody, Spark Violet™ 423 anti-mouse/human CD45R/B220 Antibody, Spark Red™ 718 anti-mouse/human CD45R/B220

Product Data



C57BL/6 mouse splenocytes stained with biotinylated RA3-6B2, followed by Sav-PE



C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for 10 minutes at room temperature and blocked with 5% FBS for 30 minutes at room temperature. Then the section was stained with 10 µg/ml of biotin anti-mouse B220 (clone RA3-6B2) and Alexa Fluor® 488 anti-mouse CD29 (clone HMβ1-1) (green) overnight at 4°C, followed by 2.5 µg/ml of Spark YG™ 570 Streptavidin (red) for 2 hours at room temperature. The image was captured by 10X objective.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587